Childhood rhabdomyosarcoma: New insight on biology and treatment

Current Oncology Reports

Volumn 12, Issue 6, 2010, Pages 402-410

  Huh, Winston W ^b   Skapek, Stephen X ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

Alveolar; Childhood; Embryonal; Insulin like growth factor; Rapamycin; Rhabdomyosarcoma; Sarcoma; Stem cell

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN; TOPOTECAN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TARGETING; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; METASTASIS POTENTIAL; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; REVIEW; RHABDOMYOSARCOMA; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELLS; MICE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECURRENCE; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; RISK FACTORS; SIGNAL TRANSDUCTION; SIROLIMUS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY; TOR SERINE-THREONINE KINASES;

EID: 78649908527     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0130-3     Document Type: Review

References (50)

1. Gurney JG, Young JL, Roffers SD, et al.: Soft tissue sarcomas. In Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Edited by Ries LAG, Smith MA, Gurney JG, et al. Bethesda, MD: National Cancer Institute SEER Program; 1999:NIH Pub. No. 99-4649.
2. S Ognjanovic AM Linabery B Charbonneau, et al. 2009 Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005 Cancer 115 4218 4226 19536876 10.1002/cncr.24465
3. PHB Sorensen JC Lynch SJ Qualman, et al. 2002 PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group J Clin Oncol 20 2672 2679 1:CAS:528:DC%2BD38XkvF2mtr0%3D 12039929 10.1200/JCO.2002.03.137 (Pubitemid 34575640)
4. D Malkin FP Li LC Strong, et al. 1990 Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 240 1233 1238 10.1126/science.1978757
5. L Sung JR Anderson C Arndt, et al. 2004 Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV J Pediatr 133 666 668
6. S Grufferman F Ruymann S Ognjanovic, et al. 2009 Prenatal X-ray exposure and rhabdomyosarcoma: a report from the Children's Oncology Group Cancer Epidemiol Biomarkers Prev 18 1271 1276 19293315 10.1158/1055-9965.EPI-08-0775
7. S Ognjanovic SE Carozza EJ Chow, et al. 2010 Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype Br J Cancer 102 227 231 1:STN:280:DC%2BC3c%2FgsleisA%3D%3D 19997102 10.1038/sj.bjc.6605484
8. RB Raney JR Anderson FG Barr, et al. 2001 Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V J Pediatr Hematol Oncol 23 215 220 1:STN:280:DC%2BD387hsVentw%3D%3D 11846299 10.1097/00043426-200105000-00008 (Pubitemid 32524925)
9. JL Meza J Anderson AS Pappo WH Meyer 2006 Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: the Children's Oncology Group J Clin Oncol 24 3844 3851 16921036 10.1200/JCO.2005.05.3801 (Pubitemid 46630730)
10. CAS Arndt JA Stoner DS Hawkins, et al. 2009 Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803 J Clin Oncol 27 5182 5188 1:CAS:528:DC%2BD1MXhsFahsLrE 19770373 10.1200/JCO.2009.22. 3768
11. O Oberlin A Rey E Lyden, et al. 2008 Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from the United States and European Cooperative Groups J Clin Oncol 26 2384 2389 18467730 10.1200/JCO.2007.14.7207
12. G Bisogno A Ferrari A Prete, et al. 2009 Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma Eur J Cancer 45 3035 3041 1:CAS:528:DC%2BD1MXhtlyjsbbJ 19783136 10.1016/j.ejca.2009.08.019
13. T Klingebiel J Boos F Beske, et al. 2008 Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high-dose chemotherapy: report of the HD CWS-96 trial Pediatr Blood Cancer 50 739 745 18286501 10.1002/pbc.21494 This provocative study demonstrates the potential efficacy of low-dose oral therapy versus high-dose therapy with stem cell rescue for high-risk patients (Pubitemid 351354776)
14. HP McDowell ABM Foot C Ellershaw, et al. 2010 Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98 Eur J Cancer 46 1588 1595 20338746 10.1016/j.ejca.2010.02.051
15. AE Donker PM Hoogerbrugge AMC Mavinkurve-Groothuis, et al. 2009 Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT Bone Marrow Transplant 43 179 180 1:STN:280:DC%2BD1M%2FpvFehtg%3D%3D 18762761 10.1038/bmt.2008.301
16. TM Dantonello C Int-Veen D Harms, et al. 2009 Cooperative Trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults J Clin Oncol 27 1446 1455 1:CAS:528:DC%2BD1MXksF2hs7o%3D 19224858 10.1200/JCO.2007.15.0466
17. S Qualman J Lynch J Bridge, et al. 2008 Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma Cancer 113 3242 3247 18985676 10.1002/cncr.23929
18. D Williamson E Missiaglia A de Reynies, et al. 2010 Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma J Clin Oncol 28 2151 2158 20351326 10.1200/JCO.2009.26.3814 This European study demonstrates that fusion gene-negative ARMS has a clinical presentation and genetic expression profile similar to ERMS, which raises the potential question of decreased intensity of therapy for this subset of patients
19. E Davicioni JR Anderson JD Buckley, et al. 2010 Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the Children's Oncology Group J Clin Oncol 28 1240 1246 1:CAS:528: DC%2BC3cXktF2ltbs%3D 20124188 10.1200/JCO.2008.21.1268
20. J Sumegi R Streblow RW Frayer, et al. 2010 Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family Genes Chromosomes Cancer 49 224 236 1:CAS:528:DC%2BC3cXmvVSmsA%3D%3D 19953635
21. M Burke JT Anderson SC Kao, et al. 2007 Assessment of response to induction therapy and its influence on 5-year failure-free survival in Group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study IV experience-a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group J Clin Oncol 25 4909 4913 17971587 10.1200/JCO.2006.10.4257 (Pubitemid 350220421)
22. DA Rodeberg JA Stoner A Hayes-Jordan, et al. 2009 Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the Children's Oncology Group J Clin Oncol 27 3705 3711 19470937 10.1200/JCO.2008.19.5933 This relevant clinical study demonstrates no relationship between radiographic response and clinical outcome in patients with group III disease
23. A Ferrari R Miceli C Meazza, et al. 2010 Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma J Clin Oncol 28 1322 1328 20124176 10.1200/JCO.2009.25.0803
24. T Volker T Denecke I Steffen, et al. 2007 Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial J Clin Oncol 25 5435 5441 18048826 10.1200/JCO.2007.12.2473 (Pubitemid 350232220)
25. U Tateishi A Hosono A Makimoto, et al. 2007 Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas J Pediatr Hematol Oncol 29 608 612 17805034 10.1097/MPH.0b013e318142b5ab (Pubitemid 47367996)
26. B Das R Tsuchida D Malkin, et al. 2008 Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction Stem Cells 26 1818 1830 18467664 10.1634/stemcells.2007-0724
27. E Charytonowicz C Cordon-Cardo I Matushansky M Ziman 2009 Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett 279 126 136 1:CAS:528:DC%2BD1MXls1yltr8%3D 19008039 10.1016/j.canlet.2008.09.039 This is an excellent review of available data on differentiating the stem cell of origin for alveolar rhabdomyosarcomas
28. YX Ren FG Finckenstein DA Abdueva, et al. 2008 Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutation Cancer Res 68 6587 6597 1:CAS:528:DC%2BD1cXpslKnurc%3D 18701482 10.1158/0008-5472.CAN-08-0859
29. AJ Wagers IM Conboy 2005 Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis Cell 122 659 667 1:CAS:528:DC%2BD2MXhtVaqu7zF 16143100 10.1016/j.cell.2005.08.021 (Pubitemid 41242632)
30. N Tiffin RD Williams J Shipley, et al. 2003 PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells Br J Cancer 89 327 332 1:CAS:528:DC%2BD3sXlsVaktrk%3D 12865925 10.1038/sj.bjc.6601040 (Pubitemid 36976324)
31. CM Linardic DL Downie S Qualman, et al. 2005 Genetic modeling of human rhabdomyosarcoma Cancer Res 65 4490 4495 1:CAS:528:DC%2BD2MXks1Ohtrc%3D 15930263 10.1158/0008-5472.CAN-04-3194 (Pubitemid 40740781)
32. SJ Odelberg A Kollhoff MT Keating 2000 Dedifferentiation of mammalian myotubes induced by msx1 Cell 103 1099 1109 1:CAS:528:DC%2BD3MXit1ajsA%3D%3D 11163185 10.1016/S0092-8674(00)00212-9 (Pubitemid 32037396)
33. C Keller BR Arenkiel CM Coffin, et al. 2004 Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function Genes Develop 18 2614 2626 1:CAS:528:DC%2BD2cXpvVykurc%3D 15489287 10.1101/gad.1244004 (Pubitemid 39453101)
34. L Kassar-Duchossoy B Gayraud-Morel D Gomes, et al. 2004 Mrf4 determines skeletal muscle identity in Myf5:Myod double-mutant mice Nature 431 466 471 1:CAS:528:DC%2BD2cXnslelsrw%3D 15386014 10.1038/nature02876 (Pubitemid 39329587)
35. Y Chen J Takita M Mizuguchi, et al. 2007 Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression Genes Chromosomes Cancer 46 348 358 1:CAS:528: DC%2BD2sXjtlGmt7o%3D 17243166 10.1002/gcc.20416 (Pubitemid 46411326)
36. E Davicioni MJ Anderson FG Finckenstein, et al. 2009 Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group Am J Pathol 174 550 564 1:CAS:528:DC%2BD1MXivVWnt78%3D 19147825 10.2353/ajpath.2009.080631
37. C De Giovanni L Landuzzi G Nicoletti, et al. 2009 Molecular and cellular biology of rhabdomyosarcoma Future Oncol 5 1449 1475 19903072 10.2217/fon.09.97 This is a good review of recent data on molecular pathways and animal models for rhabdomyosarcoma
38. S Makawita M Ho AD Durbin, et al. 2009 Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors Pediatr Develop Path 12 127 135 1:CAS:528:DC%2BD1MXkslGms70%3D 10.2350/08-05-0477.1
39. E Missiaglia J Selfe M Hamdi, et al. 2009 Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development Genes Chromosomes Cancer 48 455 467 1:CAS:528:DC%2BD1MXltlagsrs%3D 19235922 10.1002/gcc.20655
40. S Martinelli HP McDowell 2009 Delle Vigne S, et al.: RAS signaling dysregulation in human embryonal rhabdomyosarcoma Genes Chromosomes Cancer 48 975 982 1:CAS:528:DC%2BD1MXhtFGjtrbP 19681119 10.1002/gcc.20702
41. FG Barr F Duan LM Smith, et al. 2009 Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group Genes Chromosomes Cancer 48 661 672 1:CAS:528:DC%2BD1MXnvFGgs78%3D 19422036 10.1002/gcc.20673
42. E Davicioni FG Finckenstein V Shahbazian, et al. 2006 Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas Cancer Res 66 6936 6946 1:CAS:528:DC%2BD28XmvFGksbg%3D 16849537 10.1158/0008-5472.CAN-05-4578 (Pubitemid 44197668)
43. JG Taylor AT Cheuk PS Tsang, et al. 2009 Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models J Clin Invest 119 3395 3407 1:CAS:528: DC%2BD1MXhtlOitrbO 19809159
44. F Huang A Greer W Hurlburt, et al. 2009 The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining EGFR/HER2 inhibitors Cancer Res 69 161 170 1:CAS:528:DC%2BD1MXmvFCi 19117999 10.1158/0008-5472.CAN-08-0835
45. RT Kurmasheva L Dudkin C Billups, et al. 2009 The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Res 69 7662 7671 1:CAS:528:DC%2BD1MXht1Skt7jM 19789339 10.1158/0008-5472.CAN-09-1693
46. EF Petricoin III V Espina RP Araujo, et al. 2007 Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival Cancer Res 67 3431 3440 1:CAS:528:DC%2BD2sXksVGksbs%3D 17409454 10.1158/0008-5472.CAN-06-1344 (Pubitemid 46724884)
47. PJ Houghton CL Morton EA Kolb, et al. 2008 Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program Pediatr Blood Cancer 50 799 805 17635004 10.1002/pbc.21296 (Pubitemid 351354788)
48. R Sharp JA Recio C Jhappan, et al. 2002 Synergism between Ink4a/Arf inactivation and aberrant HGF/SF signaling in rhabdomyosarcoma genesis Nat Med 8 1276 1280 1:CAS:528:DC%2BD38XotlWlsrs%3D 12368906 10.1038/nm787 (Pubitemid 35373560)
49. RL Galindo JA Allport EN Olson 2006 A Drosophila model of rhabdomyosarcoma initiator PAX7-FKHR Proc Natl Acad Sci U S A 103 13439 13444 1:CAS:528:DC%2BD28XpvVakt7g%3D 16938866 10.1073/pnas.0605926103 (Pubitemid 44380126)
50. DM Langenau MD Keefe NY Storer, et al. 2007 Effects of RAS on the genesis of embryonal rhabdomyosarcoma Genes Dev 21 1382 1395 1:CAS:528: DC%2BD2sXmsFSgsbk%3D 17510286 10.1101/gad.1545007 (Pubitemid 46871041)